Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) on September 29, 2010. The report discloses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it notes that the audit opinions for the fiscal years ended December 31, 2009, and 2008 contained an explanatory paragraph disclosing uncertainty regarding the Company's ability to continue as a going concern.
Material Changes
- Accountant Change: Effective July 20, 2010, Caturano and Company, Inc. resigned as the independent auditor after its assets were acquired by McGladrey & Pullen, LLP.
- New Appointment: McGladrey & Pullen, LLP was appointed as the new independent registered public accounting firm on September 29, 2010, following a recommendation by the Audit Committee.
- Accounting Disagreements: The Company reported no disagreements with the former auditor regarding accounting principles, practices, or auditing scope during the two most recent fiscal years.
Guidance, Risks, and Contingencies
- Going Concern Risk: The filing reiterates that prior audit reports included a "going concern" qualification, indicating significant financial uncertainty.
- Accounting Changes: The 2009 audit opinion noted a change in the manner of accounting for certain warrants effective January 1, 2009.
- Consultations: The Company did not consult with the new auditor (McGladrey) on accounting principles or reportable events prior to their appointment.
Investor Verification Checklist
- Verify the current status of the "going concern" uncertainty mentioned in the 2008 and 2009 audits.
- Confirm the transition of audit responsibilities from Caturano to McGladrey & Pullen.
- Review the impact of the 2009 accounting change regarding warrant valuation on current financial statements.
- Check for any subsequent filings that may address the company's liquidity or capital needs.